Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies
• By Michael McCaughan
The debate over comparative effectiveness research has focused heavily on standards of evidence to judge the relative value of different therapies and standards for when and how conclusions should drive coverage policy. Less attention has been paid to a more fundamental question: when should the value determination be made. CMS’ top coverage official has an idea that would radically change that process.
Michael McCaughan
Everyone agrees that an ideal payment system would provide reimbursement that is commensurate with the value of the therapy. A breakthrough treatment for cancer should command a premium compared to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
